Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...

The mechanisms that enable preservation of gut mucosal integrity during persistent viral replication and inherent inflammation remain unclear. Here, we investigated, for the first time, gut ...

Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only ...

A study shows that HIV-2 is more pathogenic than previously demonstrated. The new findings indicate that early treatment should be applied to all patients with HIV, not only to those with HIV-1. A ...

There are two main types of human immunodeficiency virus (HIV) -- HIV-1 and HIV-2. Both can lead to AIDS. However, they're very different from each other. HIV-1 is the most common type. When you hear ...

This retrospective study evaluated real-world implementation of the updated CDC HIV algorithm in a large US laboratory. Objectives: To understand real-world implementation of the updated CDC HIV ...

A 53-year-old from Düsseldorf in Germany has become the third person in the world to be completely cured of HIV following a stem cell transplant using donor cells with a particular genetic mutation.

Federal health officials have approved the first at-home test to detect HIV antibodies, a move aimed at identifying and treating the estimated 20 percent of infected people in the U.S. who don’t know ...